Key facts: Novartis (NOVN) Q3 revenue +4%; net profit down 70%
Novartis (NOVN) reported Q3 2026 revenue of $14.5B (+4% YoY) and adjusted EPS of $2.46, with core operating income rising 10-11%. Net profit fell 70% to $1.2B due to a $1.9B impairment. The company raised full-year core operating income guidance and highlighted remibrutinib as a key growth driver. Novartis plans small acquisitions and will host an earnings call.
How this was made
The 30-second read
Why it matters
The earnings surprise is likely to trigger short‑term sell pressure, but the raised guidance and pipeline prospects could limit the decline.
Market read
First‑time disclosure of Q3 results for a large‑cap pharma company; material for traders and analysts.
What to watch
The $4B peak sales potential for remibrutinib may offset short‑term profit concerns.
Background
Novartis released its Q3 2026 earnings, reporting revenue growth, a sizable impairment, and an updated operating income outlook.
Ticker impact
Q3 2026 revenue up 4% YoY to $14.5B, but net profit fell 70% to $1.2B after a $1.9B impairment; full‑year operating income guidance raised to flat‑low single‑digit growth.
likely downside pressure as investors digest the large profit decline despite higher revenue and upgraded guidance
The impairment-driven profit drop is material and unexpected, outweighing the modest revenue beat and guidance lift.
Market effects
May weigh on other pharma peers as the impairment highlights pipeline risk.
Potential drag on European biotech indices.
Limited to healthcare sector; broader market likely neutral.
Counterpoint
Guidance raise could support upside if the market focuses on long‑term growth potential.
Key entities
- companyNovartis
Swiss pharmaceutical giant reporting Q3 2026 results.
